SynthesisEndocrine2014
Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients.
Synthesis in Endocrine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Culturally tailored lifestyle interventions for the prevention and management of type 2 diabetes in adults of Black African ancestry: a systematic review of tailoring methods and their effectiveness.Public health nutrition · 2022Pooled it
- Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.Clinical drug investigation · 2017Pooled it
- Pooled it
- Pooled it
- Impact of baseline characteristics on glycemic effects of add-on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus.Journal of diabetes investigation · 2020Trial
- Comprehensive Efficacy of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin in Practical Clinical Settings: A Prospective Multi-Center Interventional Observational Study.Journal of clinical medicine research · 2020Article
- Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019Article
- Post-marketing Study of Linagliptin: A Pilot Study.Frontiers in pharmacology · 2019Article
- Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.Diabetes care · 2018Article
- Slope of change in HbAEndocrinology, diabetes & metabolism · 2018Article
- Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice.BMC endocrine disorders · 2017Observational
- Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017Review
- Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.Endocrine · 2017Observational
- Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2016Article
- A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.Medicine · 2016Article
- Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: a case-control study.Journal of endocrinological investigation · 2015Article
- The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects.Journal of clinical medicine research · 2015Article
- Alogliptin benzoate for management of type 2 diabetes.Vascular health and risk management · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ability to predict which patients might benefit more of therapy might facilitate personalization of treatment. The aim of this study was to obtain information about clinical characteristics which might predict the HbA1c response to DPP-4 inhibitors. We conducted an electronic search without restriction for randomized controlled trials (RCTs) involving DPP-4 inhibitors (vildagliptin, sitagliptin, saxagliptin, linagliptin, and alogliptin). RCTs were included if they lasted at least 12 weeks, reported the effect of DPP-4 inhibitors on HbA1c level, and the number of patients in any arm was >30. We did a meta-regression analysis. Seventy-eight articles were eligible, with 79 arms and 20,503 patients. For all arms, the decrease of HbA1c was -0.74 % (95 % CI -0.80 to -0.67 %), with considerable heterogeneity (I (2) = 97 %, P < 0.0001): the greatest HbA1c decrease was seen at 52 weeks (8 arms, 3,338 patients, -0.88 %, 95 % CI -1.10 to -0.66 %). In univariate meta-regression analysis, baseline HbA1c explained 22 % of variance of the HbA1c response to treatment, while fasting glucose and type of DPP-4 inhibitor explained an additional 19 and 12 %, respectively; age, duration of treatment, previous therapy, and type of statistical analysis of RCTs were without influence. In the multivariate meta-regression model, baseline HbA1c, fasting glucose, and type of DPP-4 inhibitor explained 61 % of total variance. The HbA1c response to DPP-4 inhibitors can be modulated mainly by baseline HbA1c and fasting glucose levels: a greater absolute reduction of baseline HbA1c is seen in patients with higher baseline HbA1c and lower fasting glucose level.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.